BioMarin set to acquire Amicus after regulatory clearance

BioMarin Pharmaceutical ( (BMRN) ) has provided an announcement.

BioMarin Pharmaceutical Inc. and its wholly owned subsidiary Lynx Merger Sub 1, Inc. previously agreed on December 19, 2025, to merge Merger Sub into Amicus Therapeutics, Inc., with Amicus to survive as a wholly owned subsidiary of BioMarin. On April 23, 2026, the French Ministry of Economics and Finance granted foreign direct investment clearance, satisfying the final regulatory condition to the deal other than standard closing conditions, and the merger is now expected to close on April 27, 2026, marking a key expansion step for BioMarin in rare-disease therapeutics.

The most recent analyst rating on (BMRN) stock is a Buy with a $105.00 price target. To see the full list of analyst forecasts on BioMarin Pharmaceutical stock, see the BMRN Stock Forecast page.

Spark’s Take on BMRN Stock

According to Spark, TipRanks’ AI Analyst, BMRN is a Neutral.

The score is driven primarily by solid financial fundamentals (strong revenue growth, high gross margins, improving cash generation and low historical leverage), partially offset by 2025 margin/FCF softness. Technical signals are mixed-to-weak in the near term, valuation looks demanding at ~33x earnings with no dividend support, and recent updates add both strategic upside (Amicus deal/financing) and clinical risk (partial VOXZOGO Phase 2 dosing halt).

To see Spark’s full report on BMRN stock, click here.

More about BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for patients with rare genetic diseases. Its portfolio targets specialized, often underserved markets in the biopharmaceutical sector, where it seeks growth through both internal R&D and strategic acquisitions.

Average Trading Volume: 2,021,434

Technical Sentiment Signal: Strong Sell

Current Market Cap: $10.5B

Find detailed analytics on BMRN stock on TipRanks’ Stock Analysis page.